FBLG · FibroBiologics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Apr 30, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-23 | Cilento Richard C. Jr. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
30,803 |
| 2026-06-23 | Niklas Victoria Ninon Olivia |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
30,803 |
| 2026-06-23 | Hoffman Robert E. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
30,803 |
| 2026-06-23 | Link Matthew |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
30,803 |
| 2026-05-04 | GARCIA RUBEN A |
General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
61,607 |
| 2026-05-04 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On May 4, 2026, the reporting person was granted an option to purchase 92,410 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
92,410 |
| 2026-05-04 | Davis Jason |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
61,607 |
| 2026-05-04 | Khoja Hamid |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On May 4, 2026, the reporting person was granted an option to purchase 61,607 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods |
Stock Option (Right to Buy)
|
61,607 |
| 2026-03-04 | Khoja Hamid |
Chief Scientific Officer |
Buy↑
|
Common Stock
|
30,000 |
| 2026-03-04 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3210 to $0.4166 on March 2, 2026, $0.3885 to $0.4302 on March 3, 2026, and $0.3730 to $0.3820 on March 4, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
15,872 |
| 2026-03-03 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3210 to $0.4166 on March 2, 2026, $0.3885 to $0.4302 on March 3, 2026, and $0.3730 to $0.3820 on March 4, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
18,200 |
| 2026-03-02 | Davis Jason |
Chief Financial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3968 to $0.4200 on March 2, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
70,000 |
| 2026-03-02 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3210 to $0.4166 on March 2, 2026, $0.3885 to $0.4302 on March 3, 2026, and $0.3730 to $0.3820 on March 4, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
17,428 |
| 2026-02-27 | GARCIA RUBEN A |
General Counsel |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3221 to $0.3268 on February 27, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
40,000 |
| 2025-12-11 | GARCIA RUBEN A |
General Counsel |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3333 to $0.3504 on December 11, 2025. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
140,000 |
| 2025-06-12 | Coen Stacy Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
22,000 |
| 2025-06-12 | Niklas Victoria Ninon Olivia |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
22,000 |
| 2025-06-12 | Link Matthew |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
22,000 |
| 2025-06-12 | Hoffman Robert E. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
22,000 |
| 2025-06-12 | Cilento Richard C. Jr. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
22,000 |
| 2025-06-09 | Davis Jason |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-06-09 | Davis Jason |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On June 9, 2025, the reporting person was granted an option to purchase 450,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
450,000 |
| 2025-05-27 | Khoja Hamid |
Chief Scientific Officer |
Buy↑
|
Common Stock
|
20,000 |
| 2025-03-26 | GARCIA RUBEN A |
General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 26, 2025, the reporting person was granted an option to purchase 189,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
189,000 |
| 2025-03-26 | Khoja Hamid |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 26, 2025, the reporting person was granted an option to purchase 189,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
189,000 |
| 2025-03-26 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 26, 2025, the reporting person was granted an option to purchase 453,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one-year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
453,000 |
| 2024-12-27 | Khoja Hamid |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 27, 2024, the reporting person was granted an option to purchase 176,200 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
176,200 |
| 2024-12-27 | GARCIA RUBEN A |
General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 27, 2024, the reporting person was granted an option to purchase 176,200 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
176,200 |
| 2024-12-27 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On December 27, 2024, the reporting person was granted an option to purchase 406,339 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
406,339 |
| 2024-12-09 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Gift↓
|
Common Stock
|
100,000 |
| 2024-12-03 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Gift↓
|
Common Stock
|
50,000 |
| 2024-08-27 | Cilento Richard C. Jr. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
5,000 |
| 2024-08-27 | Hoffman Robert E. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
5,000 |
| 2024-08-27 | Niklas Victoria Ninon Olivia |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
5,000 |
| 2024-08-27 | Coen Stacy Ann |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
5,000 |
| 2024-08-27 | Link Matthew |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Stock Option (Right to Buy)
|
5,000 |
| 2024-08-12 | Khoja Hamid |
Chief Scientific Officer |
Buy↑
|
Common Stock
|
10,000 |
| 2024-08-12 | O'HEERON PETE |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiples transactions ranging from $1.82 to $2.017 on August 12, 2024. The reporting person will provide upon request to the SEC, the issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. |
Common Stock
|
8,500 |
| 2024-03-01 | GARCIA RUBEN A |
General Counsel |
Other↑
|
No Securities Owned
|
0 |
| 2024-03-01 | GARCIA RUBEN A |
General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 1, 2024, the reporting person was granted an option to purchase 180,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods. |
Stock Option (Right to Buy)
|
180,000 |